Room for improvement in the treatment of pancreatic cancer: Novel opportunities from gene targeted therapy
Michail Galanopoulos, Department of Gastroenterology, Addenbrooke’s Hospital, Cambridge CB2 0QQ, United Kingdom
Aris Doukatas, Department of Pharmacy, National and Kapodistrian University of Athens, Athens GR 15772, Greece
Filippos Gkeros, Nikos Viazis, Department of Gastroenterology, Evangelismos, Ophthalmiatreion Athinon and Polyclinic Hospitals, Athens 10676, Greece
Christos Liatsos, Department of Gastroenterology, 401 General Military Hospital, Athens 11525, Greece
Author contributions: Galanopoulos M designed the review; Galanopoulos M, Doukatas A and Gkeros F analyzed and interpreted the data; Galanopoulos M, Viazis N and Doukatas A drafted the manuscript; Liatsos C critically revised the paper; all authors have read and approved the final manuscript.
Conflict-of-interest statement: Nothing to declare.
: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Michail Galanopoulos, FEBG, MD, PhD, Doctor, Department of Gastroenterology, Addenbrooke’s Hospital, Hills Road, Cambridge CB2 0QQ, United Kingdom. firstname.lastname@example.org
Received: February 16, 2021
Peer-review started: February 16, 2021
First decision: March 28, 2021
Revised: April 11, 2021
Accepted: May 22, 2021
Article in press: May 22, 2021
Published online: June 28, 2021